Temsirolimus  ||| S:0 E:13 ||| NNP
in  ||| S:13 E:16 ||| IN
mantle  ||| S:16 E:23 ||| JJ
cell  ||| S:23 E:28 ||| NN
lymphoma  ||| S:28 E:37 ||| NNS
and  ||| S:37 E:41 ||| CC
other  ||| S:41 E:47 ||| JJ
non-Hodgkin  ||| S:47 E:59 ||| JJ
lymphoma  ||| S:59 E:68 ||| NN
subtypes  ||| S:68 E:77 ||| VBD
Temsirolimus ||| S:77 E:89 ||| NNP
,  ||| S:89 E:91 ||| ,
an  ||| S:91 E:94 ||| DT
inhibitor  ||| S:94 E:104 ||| NN
of  ||| S:104 E:107 ||| IN
mammalian  ||| S:107 E:117 ||| JJ
target  ||| S:117 E:124 ||| NN
of  ||| S:124 E:127 ||| IN
rapamycin  ||| S:127 E:137 ||| NNS
( ||| S:137 E:138 ||| -LRB-
mTOR ||| S:138 E:142 ||| NNP
) ||| S:142 E:143 ||| -RRB-
,  ||| S:143 E:145 ||| ,
has  ||| S:145 E:149 ||| VBZ
anti-tumor  ||| S:149 E:160 ||| JJ
activity  ||| S:160 E:169 ||| NN
in  ||| S:169 E:172 ||| IN
patients  ||| S:172 E:181 ||| NNS
with  ||| S:181 E:186 ||| IN
relapsed  ||| S:186 E:195 ||| NN
or  ||| S:195 E:198 ||| CC
refractory  ||| S:198 E:209 ||| JJ
mantle  ||| S:209 E:216 ||| JJ
cell  ||| S:216 E:221 ||| NN
lymphoma  ||| S:221 E:230 ||| NNS
( ||| S:230 E:231 ||| -LRB-
MCL ||| S:231 E:234 ||| NNP
)  ||| S:234 E:236 ||| -RRB-
and  ||| S:236 E:240 ||| CC
other  ||| S:240 E:246 ||| JJ
mature  ||| S:246 E:253 ||| JJ
lymphoid  ||| S:253 E:262 ||| JJ
neoplasms.  ||| S:262 E:273 ||| NNP
mTOR  ||| S:273 E:278 ||| NNP
is  ||| S:278 E:281 ||| VBZ
an  ||| S:281 E:284 ||| DT
intracellular  ||| S:284 E:298 ||| JJ
kinase  ||| S:298 E:305 ||| NN
that  ||| S:305 E:310 ||| WDT
controls  ||| S:310 E:319 ||| VBZ
the  ||| S:319 E:323 ||| DT
mRNA  ||| S:323 E:328 ||| JJ
translation  ||| S:328 E:340 ||| NN
of  ||| S:340 E:343 ||| IN
many  ||| S:343 E:348 ||| JJ
proteins  ||| S:348 E:357 ||| NNS
( ||| S:357 E:358 ||| -LRB-
eg ||| S:358 E:360 ||| UH
,  ||| S:360 E:362 ||| ,
cyclin  ||| S:362 E:369 ||| CD
D1 ||| S:369 E:371 ||| CD
)  ||| S:371 E:373 ||| -RRB-
that  ||| S:373 E:378 ||| WDT
can  ||| S:378 E:382 ||| MD
act  ||| S:382 E:386 ||| VB
as  ||| S:386 E:389 ||| IN
oncogenes  ||| S:389 E:399 ||| NNS
and  ||| S:399 E:403 ||| CC
contribute  ||| S:403 E:414 ||| VB
to  ||| S:414 E:417 ||| TO
lymphomagenesis ||| S:417 E:432 ||| VB
.  ||| S:432 E:434 ||| .
Characterized  ||| S:434 E:448 ||| VBN
by  ||| S:448 E:451 ||| IN
overexpression  ||| S:451 E:466 ||| NN
of  ||| S:466 E:469 ||| IN
cyclin  ||| S:469 E:476 ||| CD
D1 ||| S:476 E:478 ||| CD
,  ||| S:478 E:480 ||| ,
MCL  ||| S:480 E:484 ||| NNP
was  ||| S:484 E:488 ||| VBD
identified  ||| S:488 E:499 ||| VBN
as  ||| S:499 E:502 ||| IN
a  ||| S:502 E:504 ||| DT
disease  ||| S:504 E:512 ||| NN
that  ||| S:512 E:517 ||| WDT
might  ||| S:517 E:523 ||| MD
be  ||| S:523 E:526 ||| VB
susceptible  ||| S:526 E:538 ||| JJ
to  ||| S:538 E:541 ||| TO
mTOR  ||| S:541 E:546 ||| JJ
inhibition ||| S:546 E:556 ||| NN
.  ||| S:556 E:558 ||| .
When  ||| S:558 E:563 ||| WRB
single-agent  ||| S:563 E:576 ||| JJ
temsirolimus  ||| S:576 E:589 ||| NN
was  ||| S:589 E:593 ||| VBD
explored  ||| S:593 E:602 ||| VBN
in  ||| S:602 E:605 ||| IN
two  ||| S:605 E:609 ||| CD
phase  ||| S:609 E:615 ||| NN
II  ||| S:615 E:618 ||| NNP
studies  ||| S:618 E:626 ||| NNS
for  ||| S:626 E:630 ||| IN
treatment  ||| S:630 E:640 ||| NN
of  ||| S:640 E:643 ||| IN
patients  ||| S:643 E:652 ||| NNS
with  ||| S:652 E:657 ||| IN
relapsed  ||| S:657 E:666 ||| NN
or  ||| S:666 E:669 ||| CC
refractory  ||| S:669 E:680 ||| JJ
MCL ||| S:680 E:683 ||| NNP
,  ||| S:683 E:685 ||| ,
it  ||| S:685 E:688 ||| PRP
demonstrated  ||| S:688 E:701 ||| VBD
anti-tumor  ||| S:701 E:712 ||| JJ
activity ||| S:712 E:720 ||| NN
,  ||| S:720 E:722 ||| ,
with  ||| S:722 E:727 ||| IN
overall  ||| S:727 E:735 ||| JJ
response  ||| S:735 E:744 ||| NN
rates  ||| S:744 E:750 ||| NNS
of  ||| S:750 E:753 ||| IN
38 ||| S:753 E:755 ||| CD
%  ||| S:755 E:757 ||| NN
and  ||| S:757 E:761 ||| CC
41 ||| S:761 E:763 ||| CD
% ||| S:763 E:764 ||| NN
.  ||| S:764 E:766 ||| .
Subsequently ||| S:766 E:778 ||| RB
,  ||| S:778 E:780 ||| ,
a  ||| S:780 E:782 ||| DT
three-arm ||| S:782 E:791 ||| JJ
,  ||| S:791 E:793 ||| ,
randomized  ||| S:793 E:804 ||| JJ
phase  ||| S:804 E:810 ||| NN
III  ||| S:810 E:814 ||| NNP
trial  ||| S:814 E:820 ||| NN
was  ||| S:820 E:824 ||| VBD
conducted  ||| S:824 E:834 ||| VBN
to  ||| S:834 E:837 ||| TO
compare  ||| S:837 E:845 ||| VB
two  ||| S:845 E:849 ||| CD
dosing  ||| S:849 E:856 ||| JJ
regimens  ||| S:856 E:865 ||| NN
of  ||| S:865 E:868 ||| IN
temsirolimus  ||| S:868 E:881 ||| NN
with  ||| S:881 E:886 ||| IN
investigator ||| S:886 E:898 ||| NN
's  ||| S:898 E:901 ||| POS
choice  ||| S:901 E:908 ||| NN
of  ||| S:908 E:911 ||| IN
therapy  ||| S:911 E:919 ||| NN
for  ||| S:919 E:923 ||| IN
heavily  ||| S:923 E:931 ||| RB
pretreated  ||| S:931 E:942 ||| JJ
patients  ||| S:942 E:951 ||| NNS
with  ||| S:951 E:956 ||| IN
relapsed  ||| S:956 E:965 ||| NN
or  ||| S:965 E:968 ||| CC
refractory  ||| S:968 E:979 ||| JJ
MCL  ||| S:979 E:983 ||| NNP
( ||| S:983 E:984 ||| -LRB-
N  ||| S:984 E:986 ||| NNP
=  ||| S:986 E:988 ||| SYM
162 ||| S:988 E:991 ||| CD
;  ||| S:991 E:993 ||| :
randomized  ||| S:993 E:1004 ||| CD
1 ||| S:1004 E:1005 ||| CD
: ||| S:1005 E:1006 ||| :
1 ||| S:1006 E:1007 ||| LS
: ||| S:1007 E:1008 ||| :
1 ||| S:1008 E:1009 ||| LS
) ||| S:1009 E:1010 ||| -RRB-
.  ||| S:1010 E:1012 ||| .
Once-weekly  ||| S:1012 E:1024 ||| JJ
intravenous  ||| S:1024 E:1036 ||| NN
temsirolimus  ||| S:1036 E:1049 ||| VBD
175  ||| S:1049 E:1053 ||| CD
mg  ||| S:1053 E:1056 ||| NN
for  ||| S:1056 E:1060 ||| IN
3  ||| S:1060 E:1062 ||| CD
weeks  ||| S:1062 E:1068 ||| NNS
followed  ||| S:1068 E:1077 ||| VBN
by  ||| S:1077 E:1080 ||| IN
75  ||| S:1080 E:1083 ||| CD
mg  ||| S:1083 E:1086 ||| NNS
once  ||| S:1086 E:1091 ||| RB
weekly  ||| S:1091 E:1098 ||| JJ
( ||| S:1098 E:1099 ||| -LRB-
175 ||| S:1099 E:1102 ||| CD
/ ||| S:1102 E:1103 ||| CD
75 ||| S:1103 E:1105 ||| CD
)  ||| S:1105 E:1107 ||| -RRB-
significantly  ||| S:1107 E:1121 ||| RB
improved  ||| S:1121 E:1130 ||| VBN
progression-free  ||| S:1130 E:1147 ||| JJ
survival  ||| S:1147 E:1156 ||| NN
( ||| S:1156 E:1157 ||| -LRB-
hazard  ||| S:1157 E:1164 ||| NN
ratio  ||| S:1164 E:1170 ||| NN
=  ||| S:1170 E:1172 ||| SYM
0.44 ||| S:1172 E:1176 ||| CD
;  ||| S:1176 E:1178 ||| :
P  ||| S:1178 E:1180 ||| NN
=  ||| S:1180 E:1182 ||| SYM
.0009 ||| S:1182 E:1187 ||| CD
)  ||| S:1187 E:1189 ||| -RRB-
versus  ||| S:1189 E:1196 ||| CC
investigator ||| S:1196 E:1208 ||| NN
's  ||| S:1208 E:1211 ||| POS
choice  ||| S:1211 E:1218 ||| NN
therapy ||| S:1218 E:1225 ||| NN
.  ||| S:1225 E:1227 ||| .
Median  ||| S:1227 E:1234 ||| JJ
progression-free  ||| S:1234 E:1251 ||| JJ
survival  ||| S:1251 E:1260 ||| NN
durations  ||| S:1260 E:1270 ||| NNS
were  ||| S:1270 E:1275 ||| VBD
4.8  ||| S:1275 E:1279 ||| CD
and  ||| S:1279 E:1283 ||| CC
1.9  ||| S:1283 E:1287 ||| CD
months ||| S:1287 E:1293 ||| NNS
,  ||| S:1293 E:1295 ||| ,
respectively ||| S:1295 E:1307 ||| RB
.  ||| S:1307 E:1309 ||| .
The  ||| S:1309 E:1313 ||| DT
objective  ||| S:1313 E:1323 ||| JJ
response  ||| S:1323 E:1332 ||| NN
rates  ||| S:1332 E:1338 ||| NNS
were  ||| S:1338 E:1343 ||| VBD
22 ||| S:1343 E:1345 ||| CD
%  ||| S:1345 E:1347 ||| NN
in  ||| S:1347 E:1350 ||| IN
the  ||| S:1350 E:1354 ||| DT
175 ||| S:1354 E:1357 ||| CD
/ ||| S:1357 E:1358 ||| CD
75  ||| S:1358 E:1361 ||| CD
group  ||| S:1361 E:1367 ||| NN
and  ||| S:1367 E:1371 ||| CC
2 ||| S:1371 E:1372 ||| CD
%  ||| S:1372 E:1374 ||| NN
in  ||| S:1374 E:1377 ||| IN
the  ||| S:1377 E:1381 ||| DT
investigator ||| S:1381 E:1393 ||| NN
's  ||| S:1393 E:1396 ||| POS
choice  ||| S:1396 E:1403 ||| NN
group  ||| S:1403 E:1409 ||| NN
( ||| S:1409 E:1410 ||| -LRB-
P  ||| S:1410 E:1412 ||| NN
=  ||| S:1412 E:1414 ||| SYM
.0019 ||| S:1414 E:1419 ||| CD
) ||| S:1419 E:1420 ||| -RRB-
.  ||| S:1420 E:1422 ||| .
For  ||| S:1422 E:1426 ||| IN
patients  ||| S:1426 E:1435 ||| NNS
receiving  ||| S:1435 E:1445 ||| VBG
temsirolimus ||| S:1445 E:1457 ||| NN
,  ||| S:1457 E:1459 ||| ,
the  ||| S:1459 E:1463 ||| DT
most  ||| S:1463 E:1468 ||| RBS
frequent  ||| S:1468 E:1477 ||| JJ
grade  ||| S:1477 E:1483 ||| NN
3  ||| S:1483 E:1485 ||| CD
or  ||| S:1485 E:1488 ||| CC
4  ||| S:1488 E:1490 ||| CD
adverse  ||| S:1490 E:1498 ||| JJ
events  ||| S:1498 E:1505 ||| NNS
were  ||| S:1505 E:1510 ||| VBD
thrombocytopenia ||| S:1510 E:1526 ||| CD
,  ||| S:1526 E:1528 ||| ,
anemia ||| S:1528 E:1534 ||| NN
,  ||| S:1534 E:1536 ||| ,
neutropenia ||| S:1536 E:1547 ||| NN
,  ||| S:1547 E:1549 ||| ,
and  ||| S:1549 E:1553 ||| CC
asthenia ||| S:1553 E:1561 ||| NN
.  ||| S:1561 E:1563 ||| .
The  ||| S:1563 E:1567 ||| DT
results  ||| S:1567 E:1575 ||| NNS
of  ||| S:1575 E:1578 ||| IN
this  ||| S:1578 E:1583 ||| DT
trial  ||| S:1583 E:1589 ||| NN
established  ||| S:1589 E:1601 ||| VBD
a  ||| S:1601 E:1603 ||| DT
recommended  ||| S:1603 E:1615 ||| JJ
clinical  ||| S:1615 E:1624 ||| JJ
dose  ||| S:1624 E:1629 ||| NN
for  ||| S:1629 E:1633 ||| IN
temsirolimus  ||| S:1633 E:1646 ||| JJ
monotherapy  ||| S:1646 E:1658 ||| NN
in  ||| S:1658 E:1661 ||| IN
patients  ||| S:1661 E:1670 ||| NNS
with  ||| S:1670 E:1675 ||| IN
relapsed  ||| S:1675 E:1684 ||| NN
or  ||| S:1684 E:1687 ||| CC
refractory  ||| S:1687 E:1698 ||| JJ
MCL  ||| S:1698 E:1702 ||| NNP
and  ||| S:1702 E:1706 ||| CC
validated  ||| S:1706 E:1716 ||| VBG
the  ||| S:1716 E:1720 ||| DT
importance  ||| S:1720 E:1731 ||| NN
of  ||| S:1731 E:1734 ||| IN
mTOR  ||| S:1734 E:1739 ||| JJ
in  ||| S:1739 E:1742 ||| IN
the  ||| S:1742 E:1746 ||| DT
pathogenesis  ||| S:1746 E:1759 ||| NN
of  ||| S:1759 E:1762 ||| IN
advanced  ||| S:1762 E:1771 ||| JJ
MCL ||| S:1771 E:1774 ||| NNP
.  ||| S:1774 E:1776 ||| .
Objective  ||| S:1776 E:1786 ||| JJ
responses  ||| S:1786 E:1796 ||| NNS
also  ||| S:1796 E:1801 ||| RB
have  ||| S:1801 E:1806 ||| VBP
been  ||| S:1806 E:1811 ||| VBN
reported  ||| S:1811 E:1820 ||| VBN
for  ||| S:1820 E:1824 ||| IN
other  ||| S:1824 E:1830 ||| JJ
mature  ||| S:1830 E:1837 ||| JJ
B-cell  ||| S:1837 E:1844 ||| JJ
neoplasms  ||| S:1844 E:1854 ||| NNS
( ||| S:1854 E:1855 ||| -LRB-
eg ||| S:1855 E:1857 ||| UH
,  ||| S:1857 E:1859 ||| ,
diffuse  ||| S:1859 E:1867 ||| JJ
large  ||| S:1867 E:1873 ||| JJ
B-cell  ||| S:1873 E:1880 ||| JJ
lymphoma  ||| S:1880 E:1889 ||| NN
or  ||| S:1889 E:1892 ||| CC
follicular  ||| S:1892 E:1903 ||| JJ
lymphoma ||| S:1903 E:1911 ||| NN
)  ||| S:1911 E:1913 ||| -RRB-
in  ||| S:1913 E:1916 ||| IN
the  ||| S:1916 E:1920 ||| DT
phase  ||| S:1920 E:1926 ||| NN
II  ||| S:1926 E:1929 ||| NNP
setting ||| S:1929 E:1936 ||| NN
.  ||| S:1936 E:1938 ||| .
Temsirolimus  ||| S:1938 E:1951 ||| NNP
as  ||| S:1951 E:1954 ||| IN
monotherapy  ||| S:1954 E:1966 ||| NN
or  ||| S:1966 E:1969 ||| CC
in  ||| S:1969 E:1972 ||| IN
combination  ||| S:1972 E:1984 ||| NN
with  ||| S:1984 E:1989 ||| IN
other  ||| S:1989 E:1995 ||| JJ
active  ||| S:1995 E:2002 ||| JJ
agents  ||| S:2002 E:2009 ||| NNS
warrants  ||| S:2009 E:2018 ||| NNS
further  ||| S:2018 E:2026 ||| JJ
investigation  ||| S:2026 E:2040 ||| NN
for  ||| S:2040 E:2044 ||| IN
treatment  ||| S:2044 E:2054 ||| NN
of  ||| S:2054 E:2057 ||| IN
MCL  ||| S:2057 E:2061 ||| NNP
and  ||| S:2061 E:2065 ||| CC
other  ||| S:2065 E:2071 ||| JJ
non-Hodgkin  ||| S:2071 E:2083 ||| JJ
lymphomas ||| S:2083 E:2092 ||| NN
.  ||| S:2092 E:2094 ||| .
